Aerie Pharmaceuticals Inc (AERI) Position Boosted by SG Americas Securities LLC
SG Americas Securities LLC increased its holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 23.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,175 shares of the company’s stock after buying an additional 2,723 shares during the quarter. SG Americas Securities LLC’s holdings in Aerie Pharmaceuticals were worth $689,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of AERI. Teachers Advisors LLC boosted its stake in Aerie Pharmaceuticals by 5.1% during the 1st quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock valued at $2,255,000 after purchasing an additional 2,402 shares in the last quarter. California Public Employees Retirement System bought a new position in Aerie Pharmaceuticals during the 1st quarter valued at $231,000. Aperio Group LLC boosted its stake in Aerie Pharmaceuticals by 4.7% during the 2nd quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock valued at $258,000 after purchasing an additional 219 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Aerie Pharmaceuticals by 813.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 232,610 shares of the company’s stock valued at $12,223,000 after purchasing an additional 207,146 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in Aerie Pharmaceuticals by 53,632.1% during the 2nd quarter. Sei Investments Co. now owns 15,045 shares of the company’s stock valued at $790,000 after purchasing an additional 15,017 shares in the last quarter.
A number of equities analysts have issued reports on AERI shares. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 16th. Zacks Investment Research lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Mizuho initiated coverage on Aerie Pharmaceuticals in a research note on Wednesday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Finally, Cowen reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company. Aerie Pharmaceuticals has an average rating of “Buy” and a consensus price target of $71.43.
Shares of Aerie Pharmaceuticals Inc (AERI) opened at $57.40 on Thursday. Aerie Pharmaceuticals Inc has a 1-year low of $35.50 and a 1-year high of $66.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24.
TRADEMARK VIOLATION WARNING: “Aerie Pharmaceuticals Inc (AERI) Position Boosted by SG Americas Securities LLC” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://theolympiareport.com/2017/12/07/aerie-pharmaceuticals-inc-aeri-position-boosted-by-sg-americas-securities-llc.html.
Aerie Pharmaceuticals Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.